MABp1作为晚期结直肠癌新型抗体治疗:一项随机、双盲、安慰剂对照的3期研究
这项随机双盲安慰剂对照3期研究纳入对奥沙利铂和伊立替康难治的晚期结直肠癌患者,按2:1随机接受MABp1或安慰剂静脉输注每2周一次共8周。主要复合终点为第8周瘦体重稳定或增加且疼痛、疲劳、厌食三项症状中两项稳定或改善,MABp1组68例(33%)达到终点,安慰剂组19例(19%),相对风险1.76(95%CI 1.12-2.77,p=0.0045)。作者认为MABp1可能代表晚期结直肠癌管理的新标准。
要点
- MABp1组33%达到主要复合终点,安慰剂组19%,相对风险1.76(95%CI 1.12-2.77,p=0.0045)。
- 最常见3-4级不良事件为贫血、碱性磷酸酶升高、疲劳和天冬氨酸氨基转移酶升高。
- 严重不良事件发生率两组无显著差异(47例[23%] vs 33例[32%],p=0.07)。
核心结论
- 作者认为主要终点是衡量患者临床表现的有用方法,MABp1可能代表晚期结直肠癌管理的新标准。
研究设计与样本
- 正在进行的安慰剂对照随机3期试验的双盲阶段,纳入转移性或不可切除、ECOG体能状态评分1或2、存在全身炎症、体重下降及其他与预后差相关的疾病相关并发症、对奥沙利铂和伊立替康难治的患者。
- 患者按2:1随机分配接受MABp1或安慰剂,随机化代码通过交互式网络应答系统从中央保管的列表获取。
- 患者接受7.5 mg/kg MABp1或安慰剂静脉输注,每2周一次,共8周。
- 主要终点在至少接受一剂MABp1或安慰剂的患者(改良意向治疗人群)中评估,为第8周与基线相比瘦体重稳定或增加且疼痛、疲劳、厌食三项症状中两项稳定或改善的复合终点。
- 2014年5月20日至2015年9月2日入组患者,双盲阶段于2015年11月3日完成;333例患者随机分配,207例接受至少一剂MABp1,102例接受至少一剂安慰剂。
主要发现
- MABp1组68例(33%)和安慰剂组19例(19%)达到主要终点,相对风险1.76(95%CI 1.12-2.77,p=0.0045)。
- MABp1组与安慰剂组最常见的3-4级不良事件分别为贫血(8例[4%] vs 5例[5%])、碱性磷酸酶浓度升高(9例[4%] vs 2例[2%])、疲劳(6例[3%] vs 7例[7%])和天冬氨酸氨基转移酶浓度升高(6例[3%] vs 2例[2%])。
- 8周后,MABp1组17例(8%)和安慰剂组11例(11%)患者死亡,但无死亡被判定与治疗相关。
- 严重不良事件发生率在MABp1组与安慰剂组无显著差异(47例[23%] vs 33例[32%],p=0.07)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer. METHODS: Eligible patients for the double-blind phase of this ongoing, placebo-controlled, randomised, phase 3 trial, had metastatic or unresectable disease, Eastern Cooperative Oncology Group performance status score 1 or 2, systemic inflammation, weight loss, and other disease-related morbidities associated with poor prognosis, and were refractory to oxaliplatin and irinotecan. Patients were randomly assigned 2:1 to receive either MABp1 or placebo. Randomisation codes were obtained from a centrally held list via an interactive web response system. Patients received an intravenous infusion of 7·5 mg/kg MABp1 or placebo given every 2 weeks for 8 weeks. The primary endpoint was assessed in patients who received at least one dose of MABp1 or placebo (modified intention-to-treat population), and was a composite of stable or increased lean body mass and stability or improvement in two of three symptoms (pain, fatigue, or anorexia) at week 8 compared with baseline measurements. This study is registered with ClinicalTrials.gov, number NCT02138422. FINDINGS: Patients were enrolled between May 20, 2014, and Sept 2, 2015. The double-blind phase of the study was completed on Nov 3, 2015. Of 333 patients randomly assigned treatment, 207 received at least one dose of MABp1 and 102 at least one dose of placebo. 68 (33%) and 19 (19%) patients, respectively, achieved the primary endpoint (relative risk 1·76, 95% CI 1·12-2·77, p=0·0045). The most common grade 3-4 adverse events in the MABp1 group compared with in the placebo group were anaemia (eight [4%] of 207 vs five [5%] of 102 patients), increased concentration of alkaline phosphatase (nine [4%] vs two [2%]), fatigue (six [3%] vs seven [7%]), and increased concentration of aspartate aminotransferase (six [3%] vs two [2%]). After 8 weeks, 17 (8%) patients in the MABp1 group and 11 (11%) in the placebo group had died, but no death was judged to be related to treatment. The incidence of serious adverse events was not significantly different in the MABp1 group and placebo groups (47 [23%] vs 33 [32%], p=0·07). INTERPRETATION: The primary endpoint was a useful means of measuring clinical performance in patients. MABp1 might represent a new standard in the management of advanced colorectal cancer. FUNDING: XBiotech.
引用
- Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017. PMID: 28094194. doi:10.1016/S1470-2045(17)30006-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。